TABLE 3.
Summary of safety among treated patients
| Patients, n (%) | APP (n = 82) | PP (n = 81) |
|---|---|---|
| Any‐grade AE | 81 (98.8) | 78 (96.3) |
| Treatment related | 80 (97.6) | 74 (91.4) |
| Grade 3/4 AE | 54 (65.9) | 38 (46.9) |
| Treatment related | 51 (62.2) | 37 (45.7) |
| Serious AE | 32 (39.0) | 23 (28.4) |
| Treatment related | 26 (31.7) | 14 (17.3) |
| Grade 5 AE | 5 (6.1) | 7 (8.6) |
| Treatment related | 2 (2.4) | 2 (2.5) |
| AE leading to any treatment withdrawal | 13 (15.9) | 16 (19.8) |
| AE leading to any dose modification or interruption | 35 (42.7) | 21 (25.9) |
| Atezo AESI | 61 (74.4) | 34 (42.0) |
| Grade 3/4 | 8 (9.8) | 5 (6.2) |
Note: Treatment‐related AEs are related to any component of treatment. Data cutoff was July 18, 2019.
Abbreviations: AE, adverse event; AESI, AE of special interest; APP, atezolizumab plus cisplatin plus pemetrexed; atezo, atezolizumab; PP, cisplatin plus pemetrexed.